Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

Lung Cancer News – November PBAC Meeting; International Development and Reimbursement News; ESMO 2016

There are four applications for lung cancer on the November PBAC meeting agenda. Download the full agenda here. The applications are:

  • Ceritinib for ALK-positive NSCLC (locally advanced or metastatic) with progression after treatment with an ALK inhibitor
  • Nivolumab for (1) squamous and (2) non-squamous NSCLC (locally advanced or metastatic) with progression on or after chemotherapy
  • Pembrolizumab for PD-L1 positive NSCLC in patients refractory to platinum-based chemotherapy.

Beakthrough Therapy Designation has been granted by the US FDA for alectinib for patients who have not received prior treatment with an ALK inhibitor. This is based on results of the J-ALEX study conducted by Chugai in Japan, comparing alectinib with crizotinib in 207 Japanese patients with ALK-positive, advanced or recurrent NSCLC who had not been previously treated with an ALK inhibitor. Median PFS was not reached in the alectinib group compared with 10.2 months in those treated with crizotinib and a 66% improvement in PFS (HR 0.34, p<0.0001). There were also more frequent grade 3/4 adverse events in the crizotinib group (51% vs 27%). Source: FiercePharma, company press release.

Osimertinib NICE decision. Osimertinib has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to be made available through the Cancer Drugs Fund. Osimertinib will be available as a second line treatment for patients with advanced NSCLC expressing the EGFR T790M mutation. Source: FiercePharma, NICE website.

Olmutinib (HM61713) development collaboration ended. This third generation EGFR inhibitor was to be developed as a possible competitor to osimertinib; however following recent reports of severe toxicity, including the death of one patient, Boehringer Ingelheim has handed back the rights to Hanmi Pharmaceutical. Source: FiercePharma.

Data presented at ESMO. Results of KEYNOTE-024 showed pembrolizumab significantly reduced the risk of progression and prolonged overall survival compared with chemotherapy in patients with advanced NSCLC patients and high levels of PD-L1 expression. Read the NEJM article. Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients expressing PD-L1 in their tumour cells. Read the ESMO press release. UPDATE: pembrolizumab has been approved by the US FDA in first-line. Read the company press release.